2018-2020 (Grant in aid): Influences of clonal haematopoiesis in allogeneic bone marrow transplantation. Dr Paul Yeh and Professor Mark Dawson, The University of Melbourne.
Dr Paul Yeh’s research focusses on using genetic testing to study clonal haematopoiesis (CH) and how
it influences therapies in bone marrow failure. CH is a phenomenon that occurs when a genetic mutation is acquired in the haematopoietic (blood forming) stem cells of healthy individuals. At least 10-15% of ‘healthy’ people over 60 years of age have CH, and presence indicates increased risk of developing haematological malignancies and also Bone Marrow Failure Syndromes, as well as an increased risk of heart disease, stroke and death from other cancers. The first stage of Dr Yeh’s research has used highly sensitive and targeted genetic sequencing to determine if CH influences bone marrow transplant outcomes.
“Bone marrow transplantation is one of the only potential curative strategies for Bone Marrow Failure Syndromes. However, the procedure carries a significant risk of death. Also, transplant resources are extremely precious and there is a need to find better ways of improving transplant outcomes. I am using sophisticated genetic sequencing techniques to look for CH in stem cell transplant donors. I will then look to see if the presence of CH can predict the outcome of the stem cell transplant.”
The first part of Dr Yeh’s research focussed on CH and stem cell transplantation. Importantly, CH itself can be part of, or can evolve to, Bone Marrow Failure Syndromes. Not all individuals with CH will develop
or progress, and it is not precisely understood how CH leads to bone marrow failure. The next steps of his research are to explore these unanswered questions, ultimately creating a better biological understanding of how CH evolves into bone marrow failure. Much of the genetic testing component of the research has already been completed and Dr Yeh is now focussed on how this has affected stem cell transplantation. There is a large amount of data that has been generated via the genomic sequencing of samples, which requires analysis and integration with carefully curated clinical transplant databases.
Dr Yeh is the recipient of a prestigious National Health and Medical Research Council Investigator Grant, Medical Research Future Fund Priority Round 2020.
As his mentor and supervisor Professor Mark Dawson commented “Paul is definitely one of our finest next generation clinician-scientists, and we are very proud of him.” Maddie’s Vision and Snowdome similarly share this pride as he toils to discover factors that can predict transplant outcomes, significantly impacting on the lives of patients with Bone Marrow Failure Syndromes by both improving outcomes and also providing better allocation of valuable transplant resources.
2018-2020 (Grant in aid): Discovering new genes and mutations that cause failure of bone marrow neutrophil production. Professor Graham Lieschke, Australian Regenerative Medicine Institute/Monash University and The Royal Melbourne Hospital. ...Read more
2017-2019 (Grant): Predicting malignant transformation of bone marrow failure syndromes using longitudinal targeted sequencing of peripheral blood and cell-free DNA (cfDNA). Dr Piers Blombery, Peter MacCallum Cancer Centre. Dr Piers Blombery is ...Read more
2018-2020 (Grant in aid ): Identifying therapeutics which can be repurposed for the treatment of Myelodysplastic Syndromes and other Bone Marrow Failure Disorders. Dr Amee George, The Australian National University. Dr Amee George is situated at ...Read more
2020-2021 (GIA): Curation of the DIAAMOND-based Aplastic Anaemia Biobank. Associate Professor Stephen Ting, Monash University.Read more